Kimeragen regulatory update

Kimeragen said U.S. Patent No. 5,565,350 issued covering the company's chimeraplasty gene repair technology, including the composition and method of synthesizing its DNA/RNA hybrid molecules and the use of the compounds to affect changes in the DNA sequences within genes. Kimeragen holds an exclusive license to the patent, which will issue to Thomas Jefferson University in Philadelphia. ...